Prospective systematic classification of causes of death in the course of multiple myeloma - Poll - MDSpire

Prospective systematic classification of causes of death in the course of multiple myeloma

  • By

  • Jia xiang Jin

  • Britta Besemer

  • Büsranur Yilmaz

  • Mathias Hänel

  • Roland Fenk

  • Uta Bertsch

  • Kaarina-Jiayuan Gu

  • Christine Hanoun

  • Igor W. Blau

  • Christoph Mann

  • Christof Scheid

  • Roland Schroers

  • Ivana von Metzler

  • Manfred Hensel

  • Eva-Maria Klein

  • Martin Hoffmann

  • Christoph Lutz

  • Hendrik Riesenberg

  • Uwe M. Martens

  • Christian S. Michel

  • Christian Kunz

  • Evgenii Shumilov

  • Deniz Gezer

  • Tobias A. W. Holderried

  • Karolin Trautmann-Grill

  • Carsten Müller-Tidow

  • Katja C. Weisel

  • Marc S. Raab

  • Hans J. Salwender

  • Hartmut Goldschmidt

  • Elias K. Mai

  • October 20, 2025

  • 0 min

Share

Original Source(s)

Prospective systematic classification of causes of death in the course of multiple myeloma

  • by Jia xiang Jin, Britta Besemer, Büsranur Yilmaz, Mathias Hänel, Roland Fenk, Uta Bertsch, Kaarina-Jiayuan Gu, Christine Hanoun, Igor W. Blau, Christoph Mann, Christof Scheid, Roland Schroers, Ivana von Metzler, Manfred Hensel, Eva-Maria Klein, Martin Hoffmann, Christoph Lutz, Hendrik Riesenberg, Uwe M. Martens, Christian S. Michel, Christian Kunz, Evgenii Shumilov, Deniz Gezer, Tobias A. W. Holderried, Karolin Trautmann-Grill, Carsten Müller-Tidow, Katja C. Weisel, Marc S. Raab, Hans J. Salwender, Hartmut Goldschmidt, Elias K. Mai

  • October 20, 2025

Related Content

Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.

Why are long-lived plasma cells long-lived?